Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

Finckh, Axel; Tellenbach, C; Herzog, L; Scherer, A; Moeller, B; Ciurea, A; von Muehlenen, I; Gabay, Cem; Kyburz, D; Brulhart, Laure Sophie; Müller, R; Hasler, P; Zufferey, P; physicians and patients of the SCQM (Swiss Clinical Quality Management in Rheumatic Diseases)

doi:10.1136/rmdopen-2020-001174

Scientific article

English

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland

ContributorsFinckh, Axel

; Tellenbach, C; Herzog, L; Scherer, A; Moeller, B; Ciurea, A; von Muehlenen, I; Gabay, Cem; Kyburz, D; Brulhart, Laure Sophie; Müller, R; Hasler, P; Zufferey, P; physicians and patients of the SCQM (Swiss Clinical Quality Management in Rheumatic Diseases)

Published inRMD Open, vol. 6, no. 1, e001174

Publication date2020

Abstract

Multiple biologic and targeted synthetic disease-modifying rheumatic drugs (b/tsDMARDs) are approved for the management of rheumatoid arthritis (RA), including TNF inhibitors (TNFi), bDMARDs with other modes of action (bDMARD-OMA) and Janus kinase inhibitors (JAKi). Combination of b/tsDMARDs with conventional synthetic DMARDs (csDMARDs) is recommended, yet monotherapy is common in practice.

Keywords

Abatacept/therapeutic use
Adult
Aged
Antirheumatic Agents/therapeutic use
Arthritis, Rheumatoid/drug therapy
Female
Humans
Janus Kinase Inhibitors/therapeutic use
Kaplan-Meier Estimate
Logistic Models
Longitudinal Studies
Male
Middle Aged
Piperidines/therapeutic use
Prospective Studies
Pyrimidines/therapeutic use
Registries
Risk Assessment
Risk Factors
Switzerland
Tumor Necrosis Factor Inhibitors/therapeutic use

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Citation (ISO format)

FINCKH, Axel et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. In: RMD Open, 2020, vol. 6, n° 1, p. e001174. doi: 10.1136/rmdopen-2020-001174